Victoza® (liraglutide) Provides Significantly Greater HbA1c Reduction than Lixisenatide in New Clinical Trial

STOCKHOLM, Sweden, September 16, 2015 /PRNewswire/ --

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Abstract #75

Findings from a head-to-head trial comparing Victoza(R) (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs  -1.21% for lixisenatide in adults with type 2 diabetes.[1]Results from the LIRA-LIXI trial were announced today in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

The 26-week LIRA-LIXI trial compared the efficacy and safety of Victoza(R) versus lixisenatide, both as add-on to metformin in 404 people with type 2 diabetes.[1] People with type 2 diabetes treated with Victoza(R) achieved a significantly greater reduction in HbA1c versus lixisenatide at 26 weeks, meeting the trial's primary endpoint (-1.83% vs -1.21%; estimated treatment difference [ETD] -0.62% [-0.80;  -0.44]; P

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen